Dr Reddy’s Pressing On In Russia, China Approvals Add Spark

Sputnik Light Being Pursued As Universal Booster

Momentum for Dr Reddy’s in China as a string of approvals including for lenalidomide come through, while it appears to be on an even keel in Russia, a market where several foreign firms have cutback activities in the wake of the Ukraine conflict. Will the Indian firm’s Russia strategy payback?

Gains in China, Business As Usual in Russia For Dr Reddy's • Source: Shutterstock

Dr. Reddy's Laboratories Ltd. maintained that it’s been business as usual in Russia amid the Ukraine conflict, with no concerns around repatriation of dues, at least for now, while also signaling momentum in China, another market where the Indian company has had a long-standing presence. (See side box)

China Scale-Up

Dr Reddy’s is pressing ahead with plans in China, a market where it has a long-standing presence and aims to go big.

M V Ramana, Dr Reddy’s CEO, branded markets (India and Emerging Markets), indicated that China remains a focus market for the company and after the olanzapine win, the company has a lot going on.

“We brought abiraterone acetate into the market and are waiting for the group purchasing organization (GPO) to happen. But the good news is that we have recently received three approvals - deferasirox orally dissolving tablets, lenalidomide and vigabatrin,” Ramana told Scrip at the media interaction to discuss the fourth quarter earnings for fiscal year 2022.

In 2019, Dr Reddy’s emerged as the first Indian generic firm to bag a win for the supply of olanzapine under China’s new centralized drug procurement program.(Also see "Ready, Set, Lowest: Who Won China’s Latest Drug Bidding War?" - Scrip, 26 September, 2019.)

Last year the company filed about 11 products in China and expects to scale up moving into FY2023, which is the 12 months ending 31 March next year.

In the next couple of years, Dr Reddy’s expects to file 15-20 products, and receive a “good number” of approvals starting from FY23, Ramana added.

“China continues to be a focus market; what we do both in our representative office as well as our joint venture is in line with what the Chinese government is expecting us to do - bring in high quality, affordable generics, and try our best to ensure that we participate in the first GPO”.

Dr Reddy’s China subsidiary, Kunshan Rotam Reddy Pharmaceutical Co. Limited (KRRP), is a joint venture with the Rotam Group of Canada.

Earlier Dr Reddy’s CEO Erez Israeli had maintained that 70 products from the firm’s US portfolio can meet China’s regulatory requirements and registration was already underway for some of the products.(Also see "Indian Firms May Want To Slow March Into China" - In Vivo, 20 November, 2019.)

“Being there for the last 20 years, selling about $100m, about 10 products, we never left China even when it was hard and hopefully now, we can reap the benefit of it,” Israeli, Dr Reddy’s then-chief operating officer, had said at the JP Morgan Healthcare Conference in January 2019.

Dr Reddy’s co-chairman and managing director, G V Prasad, said that the Russia operations continue as such and “we are...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

Finance Watch: MapLight’s Mega-Round Funds Exploration Of Its Cobenfy Competitor

 
• By 

Private Company Edition: MapLight raised a $372.5m series D round to fund ongoing Phase II trials and investigation of additional indications for its M1/M4 muscarinic agonist. Also, Scrip spoke with Modi Ventures about its new fund.

Atai Gives Up On Recognify’s Schizophrenia Drug After Phase IIb Miss

 
• By 

Set to merge with Beckley Psytech, Atai will focus on psychedelic candidates for treatment-resistant depression while Recognify will analyze Phase IIb data for possible next steps.

EU 15% Tariff Deal Still Leaves Questions For Pharma

 

A single 15% tariff rate on imports from Europe includes pharmaceuticals, but it remains unclear if the trade deal will exclude generics or if Trump will offer a grace period.

Bayer’s Elinzanetant Is Latest Drug Hit By FDA Review Delays

 
• By 

Comes Days After PDUFA Pushback For GSK's Blenrep.

More from Scrip

EU 15% Tariff Deal Still Leaves Questions For Pharma

 

A single 15% tariff rate on imports from Europe includes pharmaceuticals, but it remains unclear if the trade deal will exclude generics or if Trump will offer a grace period.

Roche Unveils Alzheimer’s Phase III Plan And Preclinical Study

 

The trontinemab Phase III study is due to get underway this year, with Roche confident its brainshuttle technology will help it surpass approved rivals.

Bayer’s Elinzanetant Is Latest Drug Hit By FDA Review Delays

 
• By 

Comes Days After PDUFA Pushback For GSK's Blenrep.